---
title: "Bank of America Securities raises Shanghai Pharma's target price to 14 yuan, reiterates \"Buy\""
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281993938.md"
description: "Bank of America Securities raised the target price for Shanghai Pharma to HKD 14 and reiterated a \"Buy\" rating. The report noted that Shanghai Pharma's total revenue last year was RMB 283.6 billion, a year-on-year increase of 3%, in line with expectations. Due to overall pricing pressure, the bank lowered its sales forecasts for 2026 to 2028 to 2.7%, 5.8%, and 2.1%, respectively"
datetime: "2026-04-08T07:18:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281993938.md)
  - [en](https://longbridge.com/en/news/281993938.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281993938.md)
---

# Bank of America Securities raises Shanghai Pharma's target price to 14 yuan, reiterates "Buy"

Bank of America Securities published a research report indicating that Shanghai Pharma (02607.HK) had a total revenue of RMB 283.6 billion last year, a year-on-year increase of 3%, which is roughly in line with the bank's expectations.

The bank stated that to reflect the overall pricing pressure faced by Shanghai Pharma's distribution and manufacturing businesses, it has lowered the company's sales forecasts for 2026 to 2028 by 2.7%, 5.8%, and 2.1%, respectively, and adjusted its profit margin forecasts. The bank raised the company's H-share target price from HKD 13.7 to HKD 14 and reiterated its "Buy" rating

### Related Stocks

- [159316.CN](https://longbridge.com/en/quote/159316.CN.md)
- [159102.CN](https://longbridge.com/en/quote/159102.CN.md)
- [520690.CN](https://longbridge.com/en/quote/520690.CN.md)
- [589720.CN](https://longbridge.com/en/quote/589720.CN.md)
- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)
- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [516820.CN](https://longbridge.com/en/quote/516820.CN.md)
- [159992.CN](https://longbridge.com/en/quote/159992.CN.md)
- [159929.CN](https://longbridge.com/en/quote/159929.CN.md)
- [588860.CN](https://longbridge.com/en/quote/588860.CN.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [601607.CN](https://longbridge.com/en/quote/601607.CN.md)
- [159506.CN](https://longbridge.com/en/quote/159506.CN.md)
- [159938.CN](https://longbridge.com/en/quote/159938.CN.md)
- [560600.CN](https://longbridge.com/en/quote/560600.CN.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [588250.CN](https://longbridge.com/en/quote/588250.CN.md)
- [02607.HK](https://longbridge.com/en/quote/02607.HK.md)
- [520880.CN](https://longbridge.com/en/quote/520880.CN.md)
- [159837.CN](https://longbridge.com/en/quote/159837.CN.md)
- [159859.CN](https://longbridge.com/en/quote/159859.CN.md)
- [588130.CN](https://longbridge.com/en/quote/588130.CN.md)
- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)

## Related News & Research

- [Xuanzhu Biopharm Wins Green Light for Phase III Anaprazole Trial in H. pylori](https://longbridge.com/en/news/282752451.md)
- [AbbVie bets on Chinese biopharma’s pain pipeline in $745m bid](https://longbridge.com/en/news/282533515.md)
- [China to Let Firms Set New Drug Prices Based on Clinical Value, R&D Costs and Risks](https://longbridge.com/en/news/282939130.md)
- [Cutia Therapeutics’ Botox Rival Meets Phase III Goals in China](https://longbridge.com/en/news/282464943.md)
- [Anthropic adds Novartis CEO Vas Narasimhan to its board](https://longbridge.com/en/news/282719936.md)